Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

ings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company's financial results and the ability of the Company to (1) raise additional capital and continue as a going concern, (2) increase Keflex 750 sales, (3) retain marketing approval for its MOXATAG product, (4) successfully reduce costs, (5) reach profitability, (6) prove that the preliminary findings for its product candidates are valid, (7) receive required regulatory approvals, (8) successfully conduct clinical trials in a timely manner, (9) establish its competitive position for its products, (10) develop and commercialize products that are superior to existing or newly developed competitor products, (11) develop products without any defects, (12) have sufficient capital resources to fund its operations, (13) protect its intellectual property rights and patents, (14) implement its sales and marketing strategy, (15) successfully attract and retain collaborative partners, (16) successfully commercialize and gain market acceptance for its Keflex products, (17) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (18) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Two new members were ... Directors at its annual Shareholders Meeting on June 13: ... of The PFM Group, and Stephen T. Zarrilli, President ... announced the election of Michael A. DiPiano, Managing General ... and Richard P. Jaffe, Esq., of Duane Morris LLP, ...
(Date:7/22/2014)...  Neogen Corporation (NASDAQ: NEOG ) announced ... ended May 31, increased 19% from the previous year ... to the prior year,s $27,190,000. Adjusted for a 3-for-2 ... in the current year were $0.76, compared to $0.75 ... the 2014 fiscal year established new all-time highs for ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 ... di BGI, la maggiore organizzazione di genomica del mondo, ... di sequenziamento dell,intero esoma umano con base la piattaforma ... Complete Genomics, molto apprezzata nel settore per essere in ... 99.999% di precisione e una rilevazione altamente sensibile di ...
(Date:7/22/2014)... SHENZHEN, China , July 22, 2014 /PRNewswire/ ... a subsidiary of BGI, the world,s largest genomics ... new human whole exome sequencing service based on ... includes in-depth bioinformatics analysis and SNP validation, and ... 2014. Complete Genomics, highly regarded ...
Breaking Biology Technology:Two New Members Elected to University City Science Center Board of Directors 2Two New Members Elected to University City Science Center Board of Directors 3Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3
... E May Help,Prevent, Cardiovascular Events in Hp2-2 Diabetes, ... SYI ) today announced new data demonstrating that,discontinuation ... may result,in an increased risk of heart attack and ... at the Annual Scientific,Sessions of the American Heart Association, ...
... First laboratory to be certified for A1c testing using ... Heritage Labs,International LLC, a division of Hooper Holmes ... A1c testing methods by the National,Glycohemoglobin Standardization Program (NGSP)., ... hemoglobin A1c, one,for testing whole blood specimens and the ...
... 11 Amicus Therapeutics,(Nasdaq: FOLD ), today announced ... at the 5th Annual Lazard Capital Markets Healthcare,Conference in ... p.m. EST., A webcast and audio archive of ... at http://www.amicustherapeutics.com . Participants,should allow approximately five to ...
Cached Biology Technology:Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 2Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 3Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 4Heritage Labs Announces A1c Test Certification Milestone 2Heritage Labs Announces A1c Test Certification Milestone 3
(Date:7/22/2014)... by researchers in modifying properties of nanomaterials for application ... thanks to recent innovative studies conducted by scientists from ... use of a simple, efficient and low cost technique ... led by Professor Sow Chorng Haur from the Department ... that the properties of two different types of materials ...
(Date:7/22/2014)... a cost-effectiveness analysis of commercial diet programs and pills, ... the best value for the money. The Jenny Craig ... the most expensive option tested, according to researchers at ... The findings, published in the June issue of the ... health and weight-loss benefits per dollar spent as insurance ...
(Date:7/22/2014)... multinational, collaborative effort, researchers from the Icahn School of ... locations in the human genome associated with the risk ... on any psychiatric disorder to date, conducted with 80,000 ... point to biological mechanisms and pathways that may underlie ... the disorder, which has seen little innovation in drug ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3Mount Sinai scientists and international team shed new light on schizophrenia 2Mount Sinai scientists and international team shed new light on schizophrenia 3
... have determined the fine-scale genetic structure of the first ... change. , They used a high-throughput sequencing technique called ... , Their results, which focus on the pitcher ... the journal Proceedings of the National Academy of ...
... of the High Arctic climate roughly 50 million years ago ... explain how ancient alligators and giant tortoises were able to ... as they endured six months of darkness each year. ... Eocene period 52 to 53 million years ago, also has ...
... Male infertility is a common medical problem, affecting millions ... include an inability to make productive sperm. Now, using ... of Pennsylvania School of Medicine are beginning to identify ... problem. Shelley Berger PhD, the Daniel S. ...
Cached Biology News:Genetic structure of first animal to show evolutionary response to climate change determined 2Genetic structure of first animal to show evolutionary response to climate change determined 3New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 2New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 3New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 4Swimming upstream: Molecular approaches to better understand male infertility 2Swimming upstream: Molecular approaches to better understand male infertility 3
... GeneBLAzer cell-based assays utilize the membrane-permeant ... the negatively charged fluorescent beta-lactamase substrates, ... readily enter the cell, where cleavage ... them into their negatively charged forms, ...
Chlorine-36, 3.7 MBq, 100 uCi. 0.1-0.3 HCl.< 111 MBq/g Cl, < 3 mCi/g Cl.Dispensed to order. Please inquire for alternative pack sizes. Category: Radiochemicals &Radiation Safety, Radiochemicals....
Src cDNA Expression Kit (wild type)...
... Detection Kit is intended for quantitative detection ... peptides, which can result from the gradual, ... aspartic acid residues during storage or handling. ... the monitoring of charge differences for detection, ...
Biology Products: